The Oncology Institute, Inc. (TOI) Misses Q3 EPS by 1c; Offers FY22 Revenue Guidance

The Oncology Institute, Inc. (NASDAQ: TOI) reported Q3 EPS of ($0.17), $0.01 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $65 million versus the consensus estimate of $68.91 million.

GUIDANCE:

The Oncology Institute, Inc. sees FY2022 revenue of $245-250 million, versus the consensus of $270.3 million.

For earnings history and earnings-related data on The Oncology Institute, Inc. (TOI) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
• Kite Realty sells City Center in White Plains for $50 million